Optometry Times

"AC and DED are 2 of the most prevalent ocular surface disorders encountered in clinical practice," writes Rodolfo L. Rodriguez, OD, DipABO. Read the article: hubs.li/Q04gj76d0

Be on the lookout for episode 3 of From Paper to Clinic! On May 4, Drs Hamza Shah and Michael Twa's discussion on AI in eye care will go live on our website and all podcast players. In the meantime, get caught up on the latest episodes on our website: hubs.li/Q04dxJtb0

Make the most of your weekend with practical, real-world insights at the Collaborative Care Symposium. Join CCS on May 2–3, 2026, to learn from world-renowned faculty about refractive surgery, patient selection, MIGS, dry eye, and more. Register now: hubs.li/Q04f3t4W0

As women enter their 40s and 50s, many notice two profound shifts happening at once: the hormonal changes of perimenopause and menopause, and the onset of presbyopia and other vision changes. Read more: hubs.li/Q04dzSdp0 Or watch the interview: hubs.li/Q04dzSdp0

Prevent Blindness has designated April as Women’s Eye Health and Safety Month. We are proud to support this initiative and highlight the voices shaping the future of care. Explore insights from female key opinion leaders whose recent work is featured on our platforms.

On International Guide Dog Day, we recognize the incredible role guide dogs play in supporting individuals with visual impairment. Read our new article now: hubs.ly/Q04dShvn0 Image credit: Suvi Satama

Noelle Whitestone, MHA, discussed a systemic review that examined global gender disparities in access to refractive eye care services. Watch the interview: hubs.li/Q04dfg3G0

A new eye drop called motugivatrep ophthalmic suspension 0.3% (Avarept) has been released in Japan to treat DED. The approval and availability of this product introduce a new way to target the nerve pathways in the eye that cause discomfort. Read more: hubs.li/Q04cBf1Y0

Researchers at the UPMC have developed an experimental “living eye drop” that uses a naturally occurring ocular bacterium to support corneal wound healing, according to a proof-of-concept study published March 5, 2026, in Cell Reports. Read more: hubs.li/Q04c9whL0

Dry eye disease (DED) has long occupied a somewhat uneasy place in the cataract and refractive surgery workflow. It is acknowledged as a complicating factor but is often addressed reactively rather than strategically. Read more: hubs.ly/Q04c8cVX0

A fixed-dose combination of carbachol and brimonidine tartrate ophthalmic solution (Yuvezzi; Visus Therapeutics, Inc) is now available in the United States for the treatment of presbyopia in adults, following FDA approval. Read more: hubs.li/Q04brmx30

"The global rise in myopia prevalence has established myopia as a major public health concern, with projections suggesting that nearly half of the world’s population may be affected by 2050," writes Maria Liu, OD, PhD, MPH, MBA, FAAO. Read more: hubs.li/Q04bs64b0

‼️NEW SERIES ALERT‼️The debut episode of our new interview series, The Independent Series, is now LIVE on our site and Youtube page! Tune in for the first episode: hubs.li/Q04b58bw0

Join CCS - Collaborative Care Symposium on May 2-3, 2026, for an unparalleled learning experience with world-renowned faculty covering refractive surgery, cataract care, MIGS, dry eye, and more, plus practical strategies. Register today: hubs.li/Q048z1qS0

Honoring the women who are shaping the future of vision. From groundbreaking research to everyday patient care, their leadership and dedication continue to move the field forward. This Women’s History Month, we recognize their impact across every corner of eye care.

CIME returns April 19 in Los Angeles, bringing optometry and ophthalmology together for one focused day of clinical insight. Earn 6+ hours of COPE credit while exploring real-world approaches to dry eye, AMD, presbyopia, and more. Learn more: hubs.li/Q048t3Zw0

EyeCon 2026 takes place September 26–27 in Hollywood, FL, delivering two days of high-impact education, real-world clinical insights, and practical strategies you can apply immediately in practice. Secure Early Bird pricing before May 31: hubs.li/Q048wnzD0

Sydnexis has announced new data from subgroup analyses of the phase 3 STAR trial of SYD-101. The findings were presented during an oral session at the 51st Annual Meeting of AAPOS in Boston, Massachusetts, according to a news release. Read more: hubs.li/Q04877dl0

BREAKING: A handful of CRLs issued by the FDA have been announced by their respective companies. Read more on reproxalap: hubs.li/Q0476vch0 Read more on idebenone: hubs.li/Q0476tMq0

BREAKING: Johnson & Johnson announced that the US FDA has approved the TECNIS PureSee IOL, an extended depth of focus lens intended for use in cataract surgery. The lens will be available to patients in the US later this year. Read more: hubs.li/Q046wXBn0